Nano-X Imaging Ltd. current report, Q1 FY2022

Full document

Nano-X Imaging Ltd. — Form 6-K Summary

Business Context and Reporting Period

Nano-X Imaging Ltd., an Israel-based medical imaging company, furnished this Form 6-K for January 2022. The filing was signed on January 18, 2022 and reports a regulatory submission to the U.S. Food and Drug Administration (FDA).

Material Event and Product Development

  • On January 12, 2022, the company submitted an FDA Q-submission for the second version of its multi-source Nanox.ARC 3-D tomosynthesis imaging system, which produces images of human anatomies.
  • The revised system is described as improved and enhanced, including changes intended to address deficiencies identified by the FDA during review of an earlier submission made in June 2021.
  • The June 2021 submission was withdrawn to enable the Q-submission process.
  • The company previously received FDA clearance in April 2021 for its single-source Nanox Cart X-Ray System.

Financial Metrics, Liquidity, and Debt

This Form 6-K does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics. It also does not provide operating or financial results for a comparable prior period.

Guidance, Outlook, Risks, and Unusual Items

  • The filing does not provide financial guidance, commercialization timing, or a forecast for the Nanox.ARC system.
  • FDA review and any subsequent regulatory decision remain material contingencies. Submission of a Q-submission does not constitute FDA clearance or approval.
  • The withdrawal of the earlier June 2021 submission and the redesign intended to address FDA-identified deficiencies are notable regulatory developments.

Key Facts for Investor Verification

  • Verify the scope and status of the January 12, 2022 FDA Q-submission and any subsequent FDA feedback.
  • Confirm the specific deficiencies identified during review of the June 2021 submission and whether the revised system addresses them.
  • Distinguish the multi-source Nanox.ARC system from the single-source Nanox Cart X-Ray System cleared in April 2021.
  • Review later filings for FDA clearance, commercialization progress, financial results, cash usage, funding needs, and regulatory or execution risks.